| Date | Title | Description |
| 02.04.2024 | Azura Ophthalmics to Present New Data Supporting the Potenti... | —Azura to present 10 abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) an... |
| 15.02.2024 | Brandon BioCatalyst, in partnership with ANDHealth, selected... | Brandon BioCatalyst’s CUREator, in partnership with ANDHealth, is set to deliver a BioMedTech Incuba... |
| 23.01.2024 | 23 Jan 2024: Aravax closes Series B round with US$42m to acc... | Aravax, a clinical stage biotechnology company developing the first rationally designed and precisel... |
| 06.12.2023 | CatalYm Presents Positive Phase 2a Outcome for Visugromab in... | Munich, Germany, December 6, 2023 – CatalYm announced that maturing Phase 2a results from its ongoin... |
| 27.11.2023 | Enhanced Potential of Myricx’s NMT Inhibitor Payloads with D... | Scientists Uncover Central Role of N-Myristoylation in Senescence |
| 26.11.2023 | Vaxxas Announces and Publishes Successful Phase I Clinical T... | CAMBRIDGE, Mass. & BRISBANE, Australia-Vaxxas, a clinical-stage biotechnology company commercial... |
| 16.11.2023 | Certa Therapeutics presents positive data from a Phase 2 cli... | Melbourne, Australia: 16 November 2023 – Certa Therapeutics (Certa), a biotechnology company develop... |
| 15.11.2023 | Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur an... | London, UK 15 November 2023 – Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery a... |
| 02.11.2023 | PolyActiva reports promising clinical trial results for its ... | Melbourne, 1st November 2023: PolyActiva is a Melbourne-based ophthalmology company developing a nov... |
| 19.10.2023 | Myricx Bio Wins Best Poster at World ADC | London, UK, 19 October 2023 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery ... |
| 09.10.2023 | - | Brandon Capital Joins AstronauTx’ £48 million ($61 million) Series A Financing to Create New Treatme... |
| 27.09.2023 | Pathios Therapeutics Awarded Innovate UK Grant to Evaluate F... | Company Collaborating with Researchers at the University of Nottingham on Optimization and Evaluatio... |
| 27.09.2023 | Recruitment completes for second Phase III hypertension tria... | George Medicines completes recruitment of second Phase III hypertension trial investigating novel si... |
| 11.09.2023 | New Data From an Influenza Challenge Study Further Support t... | Melbourne, Australia and Milan, Italy, 11 September 2023 – ENA Respiratory, a clinical-stage pharmac... |
| 05.09.2023 | Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accompl... | BOSTON-Glyscend Therapeutics, a clinical-stage biopharmaceutical company that is reshaping the treat... |
| 27.08.2023 | Dr. Yuri Maricich joins PKG Health as its Chief Medical &... | PKG Health is pleased to announce that Dr. Yuri Maricich has joined the leadership team as Chief Med... |
| 23.08.2023 | VAXXAS AWARDED US$3.67 MILLION (AU$5.4 MILLION) FROM GLOBAL ... | Cambridge, Mass., USA, and Brisbane, Queensland, Australia – August 23, 2023 – Vaxxas, a clinical-st... |
| 15.08.2023 | CUREator+ delivers $50m funding boost to commercially focuse... | Expressions of Interest for CUREator+, a newly created $50 million program by Brandon BioCatalyst an... |
| 03.08.2023 | Cicada Innovations to launch new health-focused hub in Westm... | Australia’s flagship deep tech incubator Cicada Innovations is expanding with the opening of a healt... |
| 18.07.2023 | State Government Backs OncoRes Medical with Funding to Manuf... | Perth, 18/07/2023 – OncoRes Medical, a Perth-based medical device company, has secured $3M grant fun... |
| 06.06.2023 | Vaxxas Appoints Dr. Rochelle Chaiken as Chief Medical Office... | Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform technolo... |
| 06.06.2023 | Vaxxas Announces Interim Phase I Study Results for First Nee... | Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today a... |
| 02.06.2023 | Glyscend Therapeutics Announces Positive Topline Phase 2a Cl... | BOSTON–(BUSINESS WIRE)–Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a ne... |
| 02.06.2023 | Aravax doses first patient in Phase 2 peanut allergy clinica... | The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Ara... |
| 24.05.2023 | Nineteen groundbreaking biotech projects selected for nation... | CUREator, Australia’s national biotech incubator, today announces its second round of funding, award... |
| 22.05.2023 | EBR Systems meets endpoints early in pivotal SOLVE-CRT trial... | EBR Systems, Inc. (ASX: EBR), the medical device company developing wireless cardiac pacing systems,... |
| 22.05.2023 | EBR Systems meets endpoints early in pivotal SOLVE-CRT trial... | Melbourne, 22 May 2023 – EBR Systems, Inc. (ASX: EBR), the medical device company developing wireles... |
| 03.05.2023 | Healthcare Veteran, Zach Henderson to lead Global Kinetics a... | Charlotte, US & Melbourne, Australia – May 3, 2023, Global Kinetics, the global leader in digita... |
| 21.03.2023 | Brandon BioCatalyst, in partnership with ANDHealth, selected... | Federal investment creates a combined funding capability of $115m across programs managed by Brandon... |
| 10.03.2023 | Aravax initiates Phase 2 peanut allergy clinical trials in A... | Aravax, a clinical stage biotechnology company developing next generation immunotherapies which are ... |
| 09.03.2023 | Tech entrepreneur amongst stellar cohort in latest Women in ... | One of Australia’s most promising tech entrepreneurs joins a stellar cohort partaking in this year’s... |
| 14.02.2023 | Nasal Spray Significantly Accelerates Respiratory Virus Clea... | ENA Respiratory, a clinical-stage pharmaceutical company, announced that INNA-051, a first-in-class,... |
| 10.02.2023 | Vaxxas initiates Phase I study for needle-free seasonal infl... | Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today a... |
| 06.02.2023 | Ground-breaking results in Phase 2 scleroderma study by Cert... | Certa Therapeutics (Certa) today announces ground-breaking clinical trial data for FT011, its novel ... |
| 19.01.2023 | Coming in from the cold: needle-free patch technology for mR... | CEPI, the Coalition for Epidemic Preparedness Innovations, and Vaxxas , a clinical-stage biotechnolo... |
| 10.01.2023 | ENA Respiratory Awarded $4.38 Million U.S. Department of Def... | Clinical-stage pharmaceutical company ENA Respiratory has been awarded a $4.38 million USD agreement... |
| 20.12.2022 | Billionaires Andrew and Nicola Forrest take aim at peanut al... | Billionaires Andrew and Nicola Forrest are taking aim at peanut allergy with their new healthcare ve... |
| 20.12.2022 | Aravax commences Phase 2 development for peanut allergy ther... | Aravax, a clinical stage biotechnology company developing the first safe, convenient, and precisely ... |
| 06.12.2022 | Vaxxas Raises US$23 million (A$34 million) to Clinically Adv... | Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today a... |
| 06.12.2022 | Entact Bio Launches with $81 Million Series A to Develop Pre... | Entact Bio, the company pioneering the development of precision medicines that enhance the function ... |
| 22.11.2022 | CatalYm Closes EUR 50 Million Series C Financing to Expand a... | CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round. The... |
| 17.11.2022 | Azura Ophthalmics Announces Positive Results from Phase 2b C... | – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic cl... |
| 11.11.2022 | QUE Oncology’s non-hormonal therapy reduces hot flushes and ... | QUE Oncology announces the results of its Phase II trial of Q-122, a novel non-hormonal oral therapy... |
| 09.11.2022 | Vaxxas Announces Initiation of Phase I Clinical Study of Fir... | Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today a... |
| 09.11.2022 | Brandon Capital Invests in Neuroscience Company NRG Therapeu... | Brandon Capital, Australasia’s leading life science venture capital firm, is pleased to announce its... |
| 09.11.2022 | First Aussies to get needle-free COVID-19 vaccine patch | - |
| 04.11.2022 | Certa Therapeutics’ investigational drug FT011 delivers brea... | Certa Therapeutics’ investigational drug FT011 delivers breakthrough results as a potential novel tr... |
| 04.11.2022 | Pathios Therapeutics to Present Preclinical Data Highlightin... | - |
| 02.11.2022 | First in-human use of OncoRes Medical’s cancer imaging techn... | Quantitative Micro-Elastography (QME) Imaging System published in peer reviewed Cancer Research |
| 20.10.2022 | Azura Ophthalmics Expands Broad Intellectual Property Portfo... | Supports continued advancement of first-in-class Ophthalmic Keratolytics for ocular surface diseases |
| 12.10.2022 | Opinion: Taking the leap: transitioning from academia to ind... | Leaving academia is rarely a simple decision, no matter what career stage you are at or where you ar... |
| 28.09.2022 | Brandon Capital co-Leads USD68M Series A Financing of London... | Melbourne, Australia and London UK, 28 September 2022 –Brandon Capital, Australasia’s leading life s... |
| 21.09.2022 | Glyscend Therapeutics Releases New Phase 1 Biomarker Results... | Glyscend Therapeutics, a clinical-stage biotechnology company, today reported additional biomarker r... |
| 21.09.2022 | Azura Ophthalmics Announces Formation of Scientific Advisory... | SAB comprised of leading experts in ophthalmology to provide strategic support for the advancement o... |
| 15.09.2022 | Medisanté and George Medicines collaborate to bring Internet... | • Remote cellular-enabled blood pressure monitoring provides novel and secure way of collecting real... |
| 08.09.2022 | George Medicines provides single-pill triple combination can... | George Medicines, a late-stage drug development company focused on providing innovative and accessib... |
| 05.09.2022 | $16m cash injection to progress first-in-class therapy for i... | Australian start-up OccuRx accelerates therapy development for diseases associated with inflammation... |
| 28.08.2022 | Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clin... | Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic clas... |
| 17.08.2022 | Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for I... | Funding awarded by Brandon BioCatalyst’s CUREator |
| 27.07.2022 | Vaxxas patch worked for all Covid strains | A protein-based vaccine patch has proved effective against all major variants of Covid when given to... |
| 20.07.2022 | Australia’s first national biotech incubator announces round... | Melbourne, 20 July 2022: Australia’s national biotech incubator, CUREator today announces it is prov... |
| 19.07.2022 | CUREator, the national biotechnology incubator, backs 23 sta... | The government-backed national biotechnology incubator has made its first round of grants, worth $17... |
| 05.07.2022 | CSIRO and Australian incubator CUREator boost health securit... | $3m additional funding provided by CSIRO to CUREator, Australia’s national biotech incubator, to boo... |
| 09.06.2022 | Amaroq Therapeutics hits early milestones and makes key appo... | Promising ‘dark matter’ cancer therapy has clinical trials in sight |
| 06.06.2022 | Over $15m invested in world-leading cancer immunotherapy | University of Auckland spinout targeting new cancer treatment |
| 31.05.2022 | Vaxxas and University of Sydney complete study assessing nee... | Australian biotechnology company, Vaxxas Pty Ltd (Vaxxas), in collaboration with the University of S... |
| 18.05.2022 | Australian medical device company secures additional $12.5m ... | OncoRes Medical’s imaging system may be a game-changer for breast cancer surgeons |
| 12.05.2022 | Glyscend Therapeutics Announces Completion of Phase 1 Clinic... | Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally ... |
| 12.05.2022 | ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Deve... | ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad... |
| 10.05.2022 | Opinion: Aduhelm – Providing hope to millions of Alzheimer’s... | When I first heard the news that the FDA had approved Aduhelm – Biogen’s anti-amyloid β, disease mod... |
| 06.05.2022 | Aravax appoints Dr Brett Haumann to Board of Directors | Aravax, a clinical stage biotechnology company focused on developing the most advanced novel therapy... |
| 03.05.2022 | Australian collaboration and AU$10m investment fuels Ankere ... | Australian biotech company, Ankere Therapeutics (‘Ankere’), has launched with AU$10 million seed inv... |
| 28.04.2022 | AIC growth private equity awards: Allegro Funds, Brandon Cap... | Australian Investment Council belatedly held its 2021 awards for growth private equity firms on Thur... |
| 18.04.2022 | Parkinson’s patients benefit from revolutionary watch on the... | Patients with Parkinson’s disease are being given life-changing smart watches that allow doctors to ... |
| 12.04.2022 | Pathios Therapeutics Highlights Role of GPR65 as Critical In... | Human ex vivo data demonstrate the promise of Pathios’ ‘Macrophage Conditioning’ approach in reversi... |
| 04.04.2022 | Boosting product confidence of a world-leading RNA therapeut... | CSIRO’s Transformational Bioinformatics group validates the importance of long non-coding RNAs (lncR... |
| 24.03.2022 | Vaxxas Licenses HexaPro Spike Glycoprotein from University o... | Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch... |
| 16.03.2022 | First Participants Dosed in Phase 2a Study of Pan-Antiviral ... | ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad... |
| 09.03.2022 | Medical Research Commercialisation Fund (MRCF) renamed Brand... | The Medical Research Commercialisation Fund (MRCF), Australia and New Zealand’s largest life science... |
| 04.03.2022 | Aravax Pty Ltd announces opening of IND for Phase 2 clinical... | Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut al... |
| 23.02.2022 | ENA Respiratory and the COPD Foundation Partner to Develop P... | ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad... |
| 18.02.2022 | PolyActiva Announces Positive Phase IIa Trial Results in Low... | - |
| 17.01.2022 | Clinical trial begins in the UK to investigate 3-in-1 high b... | George Medicines, a late-stage drug development company focused on providing innovative and accessib... |
| 30.11.2021 | Q-Sera enters exclusive agreement with Terumo Corporation fo... | Q-Sera Pty Ltd, an Australian venture-backed company, today announced a partnership with Terumo Corp... |
| 27.11.2021 | Healthy Outlook: Where your super is invested | A nasal spray to prevent Covid-19, a pill to put Type 2 diabetes into remission and a wireless pacem... |
| 24.11.2021 | Silicon Valley pacemaker hopes to capture Aussie hearts with... | Silicon Valley pacemaker startup EBR Systems expects Australia’s strong research focus on heart dise... |
| 19.11.2021 | Hard WA border a boon for life sciences sector | WA’s tough border stance might make it difficult to find employees in many industries but for the St... |
| 11.11.2021 | Life science researchers and entrepreneurs encouraged to see... | Australian biotech researchers and entrepreneurs are being encouraged to apply for funding from Aust... |
| 29.09.2021 | Glyscend Therapeutics Announces Initiation of Phase 1 Clinic... | Phase 1 clinical trial currently underway in Australia investigating a noninvasive, oral polymer the... |
| 28.09.2021 | First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-... | — ENA Respiratory engages PPD, Inc. for Phase 2 COVID-19 post-exposure prophylaxis study and hVIVO f... |
| 23.09.2021 | Drug repurposing is no panacea in race to treat COVID-19 | Drug repurposing is no quick fix for developing new treatments for disease, including COVID-19, and ... |
| 16.09.2021 | Allay Therapeutics Completes Oversubscribed $60M Financing t... | Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic prod... |
| 15.09.2021 | Hope offered to Australians suffering from a rare incurable ... | A new treatment for Diffuse Systemic Scleroderma, a debilitating chronic autoimmune disease that aff... |
| 07.09.2021 | Azura Ophthalmics Appoints Biopharma Industry Veteran Steven... | Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian Gland... |
| 23.08.2021 | Australia’s first national biotech incubator established wit... | Australia’s first national biotech incubator is to be established with $40m funding from the Federal... |
| 23.08.2021 | ‘New dawn’ for biotech with taxpayer-funded incubator | The pandemic is steering the venture capital lens away from shorter-term sugar hits found in the tec... |
| 19.08.2021 | Global Kinetics Enters Remote Monitoring Business and Appoin... | Global Kinetics Pty Ltd (GK) announced today it has entered the Remote Physiologic Monitoring (RPM) ... |
| 13.08.2021 | Federal Government backs MRCF-led program to support women i... | The Brandon Capital managed-Medical Research Commercialisation Fund (MRCF), in partnership with WILD... |
| 03.08.2021 | Adelaide Type 2 Diabetes researchers zero in on an ‘operatio... | Adelaide researchers are recruiting volunteers to test “an operation in a pill” — a tablet to put ty... |
| 03.08.2021 | Glyscend Therapeutics commences South Australia Phase I clin... | Positive preclinical data suggests that Glyscend’s unique pill, mimicking gastric bypass surgery, wi... |